2016-04-28 20:41:30 UTC

Pancreatic Cancer

Chicago, IL.

Duration

31:38

About

Review of treatments for Pancreatic Cancer:

Download the session audio:

MP3 File

Download the PowerPoint presentation:

PPT File

About the Instructors

Mark Talamonti, MD

Dr. Mark Talamonti is the Vice Chairman of Surgery and Clinical Professor of Surgery at the University of Chicago Pritzker School of Medicine and the Stanton and Margaret Rogers Palmer Chairman of the Department of Surgery at NorthShore University HealthSystem based in Evanston, Illinois.  He received his undergraduate education at John Carroll University in Cleveland, Ohio where he graduated magna cum laude and was a four-year varsity football player.  He attended Northwestern University Medical School, graduating in 1983, and then completed a residency in General Surgery, which included a year as chief administrative resident, and a research fellowship in the Department of Endocrinology and Molecular Biology also at Northwestern University Medical School.  After completion of his general surgery residency, he pursued a fellowship in Surgical Oncology in the Department of Surgery at the University of Texas, MD Anderson Cancer Center in Houston.   His clinical expertise focuses on the area of gastrointestinal surgical oncology with specific interests in pancreas, liver, and gastric cancers.  He has authored over 125 peer reviewed scientific publications, as well as 25 book chapters and has edited two books on Liver Surgery and Gastrointestinal Oncology.  Dr. Talamonti serves on the Editorial Board for the Annals of Surgical Oncology and the Journal of Surgical Oncology.  He leads a multi-faceted department which is clinically one of the most critical programs in a nationally recognized regional health care system with over 700 employed physicians, four hospitals and 75 practice entry sites.    

More on Pancreatic Cancer

Stepped-Up Moves to Understand, Diagnose IBD-Related Autoimmune Pancreatitis

Oct. 12, 2017

Possible genetic overlap; concurrence shown to affect clinical course, pancreatic cancer risk.

Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis

Oct. 11, 2017

We found that low-risk IPMNs have almost 8% chance of progressing to pancreatic cancer within 10 years.

Congressional Committees Approve Increase for NIH Funding

Sept. 13, 2017

Senate bill includes funding for gastrointestinal disorders and cancers.